The Future of RNA Therapeutics
AVI BioPharma is focused on the discovery and development of RNA–based drugs utilizing an extensive proprietary technology platform with applications to a range of diseases and genetic disorders.
AVI’s lead clinical RNA–based drug programs are evaluating treatments for Duchenne muscular dystrophy. Our antiviral programs have demonstrated promising effects in Ebola Zaire and Marburg Musoke viruses and may prove applicable to other viral targets such as influenza, HCV and Dengue viruses.
AVI BioPharma — Advancing RNA Drug Development and Discovery to Improve Human Medicines